{"id":"NCT00369343","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women","officialTitle":"A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-11","completion":"2008-07","firstPosted":"2006-08-29","resultsPosted":"2012-05-07","lastUpdate":"2012-05-07"},"enrollment":381,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression","Depressive Disorder","Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal.","primaryOutcome":{"measure":"Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.","timeFrame":"Baseline to 8 weeks","effectByArm":[{"arm":"Desvenlafaxine Succinate Sustained-Release (DVS SR)","deltaMin":-12.64,"sd":0.53},{"arm":"Placebo","deltaMin":-8.33,"sd":0.74}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":37,"countries":["United States"]},"refs":{"pmids":["25860107","20797382"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Headache","Dry mouth","Nausea","Constipation","Somnolence"]}}